News
Important Only
NATO's Rutte says Iran must not develop nuclear weapons
THE HAGUE, June 23 (Reuters) - Iran must not develop nuclear weapons, NATO's Secretary General Mark Rutte said on Monday."Allies have repeatedly urged Iran to meet its obligations under the non-proliferation treaty," he told reporters ahead of a two-day summit of the Alliance in The Hagu...Reuters
Mon, Jun 23
Rockcliffe Capital Initiates Coverage On Agnico Eagle Mines Ltd With A "Strong Buy" Rating And C$155 Price Target
June 23 (Reuters) - Agnico Eagle Mines Ltd AEM.TO:ROCKCLIFFE CAPITAL INITIATES COVERAGE ON AGNICO EAGLE MINES LTD. (TSX/NYSE: AEM) WITH A "STRONG BUY" RATING AND C$155 PRICE TARGETReuters
Mon, Jun 23
S&W Seed Co Terminated President And CEO Mark Herrmann On June 18,
June 23 (Reuters) - S&W Seed Co SANW.O:S&W SEED CO - ON JUNE 18, MARK HERRMANN TERMINATED AS PRESIDENT AND CEO - SEC FILINGS&W SEED CO - VANESSA BAUGHMAN APPOINTED INTERIM CEO - SEC FILINGSource text: [ID:n0001641172-25-016005]Reuters
Mon, Jun 23
Microstrategy Inc - Shareholder Derivative Suit Filed Against Microstrategy Officers And Directors
June 23 (Reuters) - Microstrategy Inc MSTR.O:MICROSTRATEGY INC - SHAREHOLDER DERIVATIVE SUIT FILED AGAINST MICROSTRATEGY OFFICERS AND DIRECTORS - SEC FILINGMICROSTRATEGY INC - INTENDS TO VIGOROUSLY DEFEND AGAINST CLAIMS - SEC FILINGReuters
Mon, Jun 23
Cushman & Wakefield Announces Changes To Its Board Of Directors
June 23 (Reuters) - Cushman & Wakefield PLC CWK.N:CUSHMAN & WAKEFIELD ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORSCUSHMAN & WAKEFIELD PLC - RETIREMENT OF BRETT WHITE AS CHAIRMANCUSHMAN & WAKEFIELD PLC - APPOINTMENT OF STEVE PLAVIN AS CHAIRMAN AND INDEPENDENT DIRECTORReuters
Mon, Jun 23
Zooz Power Explores Strategic Opportunities As Leading Defense Company Commences Poc For Flywheel-Based Power Booster
June 23 (Reuters) - Zooz Power Ltd ZOOZ.TA:ZOOZ POWER EXPLORES STRATEGIC OPPORTUNITIES AS LEADING DEFENSE COMPANY COMMENCES POC FOR FLYWHEEL-BASED POWER BOOSTERZOOZ POWER: BOARD APPROVES COMPANY-WIDE COST REDUCTION & RESTRUCTURING INITIATIVE TO REDUCE OPERATING COSTS BY ABOUT 35%Reuters
Mon, Jun 23
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
June 23 (Reuters) - Revolution Medicines Inc RVMD.O:REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER WITH KRAS G12 MUTATIONSREVOLUTION MEDICINES INC - DESIGNATION BASED ON DATA FROM PHASE 1 TRIALREVOLUTION MEDICIN...Reuters
Mon, Jun 23
